Top Companies in Human Microbiome Market

The Human Microbiome market is expected to reach USD 4.21 billion in 2030 from USD 0.81 billion in 2024, at a CAGR of 31.5% during the forecast period. The major factors driving the growth of the microbiome-based drugs market are the advancements in microbiome sequencing techniques. Improved sequencing methods enable precise analysis of microbiome composition and dynamics, which stimulates research, attracts investment, and accelerates the development of microbiome-based products, expanding market opportunities and applications.

These advancements have given rise to a whole new segment in the form of the gut-microbiome sequencing industry improving the development of microbiome biome-based therapies. Moreover, an increase in the demand for personalized services is another factor that is expected to drive growth in this market. The human microbiome market is dynamic wherein, the human microbial therapy market space is consolidated with currently only two drugs approved in the US for microbiome modulation, VOWST (Seres Therapeutics) and Rebyota (Ferring Pharmaceuticals), both targeting Clostridioides difficile infections.

To know about the assumptions considered for the study download the pdf brochure

Collectively, the human microbiome (drugs, probiotics, prebiotics, and synbiotics) market is consolidated, with the top players like Seed Health, Inc. (US), International Flavors & Fragrances, Inc. (US), Seres Therapeutics, Inc (US), Ferring Pharmaceuticals (Switzerland), and Pendulum (US). These players have adopted various strategies such as conducting clinical trials, new product launches, acquisitions, agreements, partnerships, and geographical expansions to strengthen their position in the human microbiome market. In November 2024, Microbiotica began a Phase 1b clinical trial of MB310, a microbiome treatment for ulcerative colitis (UC). Furthermore, ongoing research studies of the human microbiome are also driving market growth. For example, in February 2025, researchers at the National University of Singapore created a Gut Microbiome on a Chip (GMoC) platform to simulate the human-gut micro environment, allowing real-time monitoring of microbial interactions.

Seres Therapeutics, Inc. (US)

Seres Therapeutics is one of the emerging players in the human microbiome market. The company’s microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market. Its R&D expenses were USD 145 Million for the year ended December 31, 2023. Seres Therapeutics has collaborated with various companies like Nestlé and Bacthera as their products advance clinical development, re-evaluate the clinical development of SER-287, and evaluate the potential to utilize biomarker-based patient selection and stratification in future clinical development efforts.

Ferring Pharmaceuticals (Switzerland)

Ferring Pharmaceutical’s revenue has seen a growth, owing to Ferring being the first company to receive approval for their fecal microbiota transplant product in the US which rendered them a key player in the human microbiome market space. They have emerged as a leading player through a combination of Organic and inorganic growth strategies bolstered by Regulatory approvals, Product Launches, Collaborations, and Strong R&D. Their collaboration with PharmaBiome (Switzerland) in December 2023 is indicative of their commitment to develop and innovate in Human Microbiome Space.

Seed Health, Inc. (US)

Seed Health offers unique products such as Synbiotics in their portfolio which makes them stand out from the herd. Apart from their product offerings, Seed Health also has various collaborations such as their collaboration with the Swiss Institute of Allergy and Asthama Research (SAIF) which enabled them to launch their platform to develop next-generation human microbiome products, agreements, and several products in pre-clinical phases which makes them a leader in Human Microbiome Market. This is further emphasized by their acquisition of augGI Technologies, Inc.(US) which is a digital health company with a suite of artificial intelligence and machine learning technologies to track and analyze digestive health. Seed Health Inc. aims to utilize its technology to improve adherence and outcomes in its products. Hence this instance also showcases Seed Health’s vision for the future by utilizing AI and machine learning technologies to further develop the next generation of synbiotics and probiotics.

Related Reports:

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com